CBIO · Insider Trading
Crescent Biopharma, Inc. Common Stock
Every open-market purchase and sale reported by CBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-10-31 | GNI Group Ltd. | 10%+ Owner | Buy | +16,222,222 deriv. | — |
| 2023-10-27 | GNI Hong Kong Ltd | 10%+ Owner | J | −5,371,304 | — |
| 2023-09-01 | Seline E. Miller | SVP Finance; Interim CFO & PAO | D | −6 | — |
| 2023-09-01 | Augustine Lawlor | Director | D | −48 | — |
| 2023-09-01 | Nassim Usman | President & CEO | D | −34 | — |
| 2023-09-01 | Andrea Hunt | Director | D | −28 | — |
| 2023-09-01 | GNI Group Ltd. | 10%+ Owner | D | −12,533 | — |
| 2022-08-10 | Grant E. Blouse | Chief Scientific Officer | Buy | +3,250 | +$1.53K |
| 2022-08-10 | Seline E. Miller | SVP Finance; Interim CFO & PAO | Buy | +3,250 | +$1.53K |
| 2022-08-10 | Nassim Usman | President & CEO | Buy | +3,250 | +$1.53K |
| 2022-02-23 | Seline E. Miller | SVP Finance; Interim CFO & PAO | A | +107,500 deriv. | — |
| 2022-02-23 | Grant E. Blouse | Chief Scientific Officer | A | +200,000 deriv. | — |
| 2022-02-16 | Seline E. Miller | SVP Finance; Interim CFO & PAO | Buy | +3,250 | +$1.50K |
| 2022-02-16 | Grant E. Blouse | Chief Scientific Officer | Buy | +3,250 | +$1.50K |
| 2022-02-16 | Nassim Usman | President & CEO | Buy | +3,250 | +$1.50K |
| 2022-01-07 | Eddie Williams | Director | A | +12,308 | — |
| 2022-01-07 | Geoffrey M.D. Ling | Director | A | +12,855 | — |
| 2022-01-07 | Andrea Hunt | Director | A | +7,521 | — |
| 2021-10-05 | Geoffrey M.D. Ling | Director | A | +2,858 | — |
| 2021-10-05 | Errol B Desouza | Director | A | +3,588 | — |
| 2021-10-05 | Andrea Hunt | Director | A | +1,824 | — |
| 2021-10-05 | Eddie Williams | Director | A | +2,980 | — |
| 2021-10-05 | Augustine Lawlor | Director | A | +5,839 | — |
| 2021-09-13 | Jeanne Y Jew | Director | A | +28,000 deriv. | — |
| 2021-08-11 | Grant E. Blouse | Chief Scientific Officer | Buy | +1,163 | +$4.21K |
| 2021-08-11 | Howard Levy | Chief Medical Officer | Buy | +639 | +$2.31K |
| 2021-08-11 | Nassim Usman | President & CEO | Buy | +867 | +$3.14K |
| 2021-07-02 | Andrea Hunt | Director | A | +2,886 | — |
| 2021-07-02 | Eddie Williams | Director | A | +1,414 | — |
| 2021-07-02 | Errol B Desouza | Director | A | +3,406 | — |
| 2021-07-02 | Augustine Lawlor | Director | A | +5,542 | — |
| 2021-07-02 | Geoffrey M.D. Ling | Director | A | +2,713 | — |
| 2021-07-02 | Sharon Tetlow | Director | A | +14,000 deriv. | — |
| 2021-04-26 | Clinton Musil | Chief Financial Officer | A | +54,000 deriv. | — |
| 2021-04-26 | Nassim Usman | President & CEO | A | +140,000 deriv. | — |
| 2021-04-26 | Howard Levy | Chief Medical Officer | A | +25,000 deriv. | — |
| 2021-04-07 | Nassim Usman | President & CEO | M | +5,000 | +$23.15K |
| 2021-04-05 | Eddie Williams | Director | A | +1,215 | — |
| 2021-04-05 | Andrea Hunt | Director | A | +2,480 | — |
| 2021-04-05 | Augustine Lawlor | Director | A | +4,761 | — |
| 2021-04-05 | Geoffrey M.D. Ling | Director | A | +2,331 | — |
| 2021-04-05 | Errol B Desouza | Director | A | +2,926 | — |
| 2021-02-22 | Nassim Usman | President & CEO | Buy | +582 | +$2.80K |
| 2021-02-22 | Howard Levy | Chief Medical Officer | Buy | +1,670 | +$8.03K |
| 2021-02-10 | Nassim Usman | President & CEO | A | +140,000 deriv. | — |
| 2021-02-10 | Howard Levy | Chief Medical Officer | A | +25,000 deriv. | — |
| 2021-02-10 | Clinton Musil | Chief Financial Officer | A | +54,000 deriv. | — |
| 2021-01-06 | Errol B Desouza | Director | A | +2,129 | — |
| 2021-01-06 | Andrea Hunt | Director | A | +1,881 | — |
| 2021-01-06 | Augustine Lawlor | Director | A | +3,417 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.